ASH 2024: Polycythemia Vera and Myelofibrosis: Current and Future Standards of Care - Episode 13

Advancing Myelofibrosis Treatment: Personalized Strategies with Fedratinib and Ruxolitinib

, , , ,

Panelists discuss data from the FREEDOM2 trial and its sub-analysis on low platelet count with fedratinib (FEDR), as well as the pooled analysis of the COMFORT-I/-II trials on ruxolitinib (RUX) for myelofibrosis.

EP. 1: Initial Treatment Strategies for Polycythemia Vera
EP. 2: Cytoreductive Therapy in PV Treatment Paradigm
EP. 3: JAK Inhibition in Polycythemia Vera: Treatment Updates
EP. 4: Interferon Therapy in PV
EP. 5: Safety Considerations for PV Therapy
EP. 6: Evolving Treatment Strategies in Polycythemia Vera: Insights Ffrom Trials and Real-World Evidence
EP. 7: Interferon Real- World Treatment Patterns in PV
EP. 8: Considerations for Polycythemia Vera Management: Patient Monitoring, Outcomes, and Risks
EP. 9: Future Considerations for Polycythemia Vera Management: Takeaways from ASH 2024
EP. 10: An Overview to Myelofibrosis and Disease Risk
EP. 11: Treatment Goals for Myelofibrosis
EP. 12: Personalizing Therapy in Myelofibrosis: Insights from Key Clinical Trials
Now Viewing
EP. 13: Advancing Myelofibrosis Treatment: Personalized Strategies with Fedratinib and Ruxolitinib
EP. 14: Real-World Data in Myelofibrosis: Bridging the Gap Between Clinical Trials and Practice

Video content above is prompted by the following:

• Dr Harrison: Fedratinib (FEDR) - FREEDOM2
o FFREEDOM2, Sub-analysis on low plt count
• Dr Gangat: RUX, COMFORT-I/-II Pooled Analysis

Related Content:

ASH 2024: Polycythemia Vera and Myelofibrosis: Current and Future Standards of Care Video SeriesOncLive Peer Exchange®
Real-World Data in Myelofibrosis: Bridging the Gap Between Clinical Trials and Practice
Key Updates in the Treatment of ES-SCLC
Expert Insights on Recent Advancements in LS-SCLC